CHINAPLAS
The operating environment for most industries became increasingly complex. It is more vital than ever for enterprising businesses to master technological innovation. CHINAPLAS , the Asia’s No. 1 plastics and rubber trade fair, offers an international platform for the release and exchange of advanced new technologies. The show will not only feature more than 3,500 exhibitors but will also organize a series of exciting concurrent events to address those industries’ needs.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190311005047/en/
Plastics Recycling & Circular Economy Conference and Showcase
To foster circular economy is a global consensus to achieve sustainable development. Great potential and bounteous market opportunities arise with it. More and more big brands have announced environmental protection policies of recycling. In 2017, Adidas sold 1 million pairs of running shoes made of ocean plastic waste. How can plastics contribute to sustainable development? Focusing on the concerns of the industry, a “Plastics Recycling & Circular Economy Conference and Showcase ”, will be held with the themes of “Material Science for Sustainability”, “Recycling Technology” and “Environmental Packaging”.
Industry 4.0 Factory of the Future
Industry practitioners can visit the “Industry 4.0 Factory of the Future ” at CHINAPLAS 2019. There will be two themed areas, “Manufacturing Intelligence Control Room” and “Smart Factory”, to demonstrate implementable intelligent solutions. The control room will display operational data recorded at both the on-site machines and a remote smart factory, while the “Smart Factory” will simulate the future manufacturing environment.
Design x Innovation
Recognizing the key role of design in product development, CHINAPLAS 2019 will organize the event “Design x Innovation ”, comprising three parts.
1. CMF Inspiration Walls will display rich resources on Color, Material and Finish.
2. Design Forum will share product experience covering recyclable & sustainable design, low carbon design and CMF applications.
3. CHINAPLAS Designers’ Night .
Tech Talk
By way of open forums, “Tech Talk ” will showcase the hottest product technologies, and focus clearly on cutting-edge solutions. Tech Talk will include 11 major themes, including new energy vehicles, automotive thermoplastic elastomers, 3D printing, Bioplastics, composites, antimicrobial applications, in-mold labeling, precision extrusion, green building solutions, plastics for wearable electronics, long fiber injection molding.
Medical Plastics Connect
“Medical Plastics Connect ” actively promotes medical-grade chemical raw materials and equipment to create an efficient communication platform for medical device, consumables, and pharmaceutical packaging manufacturers. These activities aim to pinpoint for potential buyers the unique medical plastics technologies among the many exhibits active in this sector. "Medical Plastics Connect” activities include “Open Forum”, “Pop-up Kiosk”, “Medical Plastics Guidebook” and “Medical Plastics Guided Tour”.
CHINAPLAS , the Asia’s No. 1 plastics and rubber trade fair, will be held in Guangzhou, PR China, from May 21-24, 2019. An estimated total of over 3,500 exhibitors from all over the world will be presenting to more than 180,000 professional visitors from 150 countries and regions. For more information and pre-registration, please click here .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190311005047/en/
Contact:
Stella Yuen Chinaplas.PR@adsale.com.hk
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release
- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c
Qualcomm Announces Quarterly Cash Dividend17.10.2025 15:00:00 CEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom